News

Finanz und Wirtschaft: Doubts about the market for corona boosters

24 June 2022

RocketVax SARS-CoV-2 Vaccine (RVX-sCPD9) Significantly Outperforms mRNA and Adenovirus Vector-Based Technologies in Animal Models

9 June 2022

RocketVax strengthens its technology portfolio and Covid-19 vaccine development through broad-based partnerships

16 March 2022

Dr. Vladimir Cmiljanovic is the recipient of the 2021 Nikola Tesla Award for the achievements in the field of science

12 November 2021

RocketVax successfully raises CHF 7.2 million of seed funding

3 August 2021

Batavia Biosciences to develop innovative clinical process for RocketVax’s second generation COVID-19 vaccine

6 July 2021

Basel government approves one million for research to develop novel vaccine against SARS-CoV-2 coronavirus

17 June 2021

RocketVax AG and Swiss Rockets AG expand science and leadership teams

3 June 2021

Innosuisse supports the Basel biotech company RocketVax in its research into the second generation of SARS-CoV-2 vaccines

16 April 2021

Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

10 November 2020